Medicare Boosts Reimbursement for Oncocyte’s Flagship Technology

IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a diagnostics technology company, today provided a positive update on pricing for its next-generation lab-developed test (LDT), GraftAssureCore. The new reimbursement rate strengthens the company’s position in the growing transplant rejection testing market and suggests potential upside to its estimated $1 billion total addressable market.

Read more at globenewswire.com